Summary
The study is researching an experimental drug called linvoseltamab in combination with
other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab
has previously been studied as a single agent (without other cancer treatments) in
participants with multiple myeloma that returned after prior therapies and needed to be
treated again.
In the initial study, some participants treated with linvoseltamab had improvement of
their myeloma, including complete responses (no evidence of myeloma in their bodies).
This study is the first time linvoseltamab will be combined with other cancer therapies.
The main goal is to understand if linvoseltamab can be given safely with other cancer
treatments, and if so, what dose of linvoseltamab should be used for each combination.
The study is looking at several other research questions, including:
- How many participants treated with linvoseltamab in combination with each of the
other cancer treatments have improvement of their multiple myeloma
- What side effects may happen from taking linvoseltamab together with another cancer
treatment
- How much study drug is in your blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug
less effective or could lead to side effects)